WWOX is a cancer gene, spanning the common chromosomal fragile site 16D. Genomic and expression aberrations affecting this gene and locus are common in various neoplasias including breast cancer. The aim of the present study was to evaluate the relationship between WWOX expression at the protein level with respect to clinico-pathological characteristics. We performed immunohistochemical analyses on breast specific tissue microarrays representing, human normal breast epithelium (n=16), ductal carcinoma in situ (n=15) and invasive breast cancer cases (n=203). Staining intensity measurements were objectively determined utilizing an image analysis system. Western blot analyses were also performed on an independent set of 23 invasive breast carcinomas. All normal breast epithelial samples express WWOX protein abundantly while 34% (69/203 cases) of invasive breast carcinomas were 'completely negative' for WWOX expression and an additional 26% (52/203) of cases expressed WWOX very weakly. For DCIS samples five out of 15 (33%) were negative or weak for WWOX staining. Interestingly, we found a statistically significant correlation between WWOX expression and estrogen receptor (ER) status, 27% of ER+ breast carcinomas were completely negative for WWOX expression versus 46% for ERÀcases ( p = 0.0054). Furthermore, when negative plus weakly WWOX stained cases were considered the difference became more significant with 51% of ER+ cases and 73% for the ER À group, with a p=0.003. These data indicate that loss of WWOX expression is a common event in breast cancer. It is unclear at this point whether loss of WWOX expression is a consequence of tumor progression or represents a subclass of breast carcinomas. The strong association of WWOX expression with ER status reinforces the suggested role of this protein as an enzyme involved in sex steroid metabolism.
Introduction
Genomic and gross chromosomal abnormalities in breast cancer affecting the long arm of chromosome 16 have been frequently reported over the years [1] [2] [3] [4] . It was further observed that allelic losses affecting various regions of 16q already occur at pre-invasive stages of carcinoma development [4] [5] [6] . In studies from our laboratory we identified the ch16q23.1-24.1 region as having the highest incidence of allelic losses in DCIS lesions [6] . We followed up these studies by the cloning of WWOX, the gene spanning the second most common chromosomal fragile site, FRA16D [7] . Since then, abnormalities affecting WWOX at the genomic and expression level were reported in numerous neoplasias including, breast, ovarian, esophageal, liver and other carcinomas and leukemias [7] [8] [9] [10] . We also observed that ectopic WWOX expression was able to inhibit anchorage independent growth and in vivo tumorigenicity of highly aggressive breast carcinoma lines, suggesting a putative tumor supressor role for this novel protein [11] .
WWOX encodes a 46 kD protein that contains two WW domains and a short chain oxidoreductase (SDR) domain. Little is known of the biochemical function(s) of WWOX. The SDR domain is predicted to be involved in sex-steroid metabolism and the WW domains are likely involved in protein-protein interactions [7, 12, 13] .
In this report we analyzed WWOX protein expression levels by means of Western blot and tissue microarray (TMA) immnuhistochemistry analyses on breast specimens correlating with clinico-pathological features. 
Material and methods

Breast tissue microarrays
Immunostaining method
Prior to anti-WWOX immunostaining, endogenous peroxidase activity was blocked with 3% H2O2 in water for 10 min. Heat-induced epitope retrieval was performed with 1.0 mM EDTA Buffer pH 8.0 for 10 min in a microwave oven followed by a 20 min cool down. In order to block non-specific antibody binding, tissue sections were incubated with 10% goat serum in PBS for 30 min. Primary polyclonal rabbit WWOX antibody (140 lg/ml) was used at a 1:50 dilution overnight at 4°C. This was followed by incubation with Envision plus labeled polymer, anti-rabbit-HRP antibody (Dako) for 30 min at room temperature. Staining development was performed with DAB with timed monitoring using a positive control sample. The slides were then counterstained with hematoxylin, dehydrated, cleared and mounted.
Evaluation of anti-WWOX immunohistochemical staining
Anti-WWOX staining intensity was measured using a Chromavision Automated Cellular Imaging System (ACIS Ò ). For performing such measurements we utilized the generic DAB software application provided by ACIS Ò . The area of each individual TMA core was considered for the measurements in its totality. The software determines brown intensity (i.e. positive stained cells) regardless of the area covered by the positive cells. The cutoff to establish positive and negative staining was determined to be at a mean intensity of 63 (arbitrary units) over a total of 255 (color saturation scale). Therefore, cores with values 63 were 'completely negative' for WWOX immunostaining, no brown detected. Between 63 and 70 values were determined to fall in the 'weak' staining category. Cores with staining intensity values >70 were considered to fall in the 'strong' staining category.
Western blot analysis
Total protein extracts were prepared from a set of 23 human breast IDCA samples obtained from the cooperative human tissue network (CHTN). As normal controls we used protein extracts from human breast epithelial organoids, obtained from mammoplasty specimens (CHTN). As negative control we used protein extracts from the ovarian cell line PEO1, known not to express WWOX due to a homozygous deletion affecting this gene (8) . Total cell protein lysates were made from frozen tissues using RIPA buffer (50 mM Tris pH7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% SDS) containing protease inhibitor cocktail (Roche, Mannheim, Germany). For western blotting 50 lg of total protein was separated by 12.5% SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA). Immunodetection was performed using Protein Detector TM (KPL, Gaithersburg, MD) western blotting reagents as described by the manufacturer. WWOX protein was detected using affinity purified anti-WWOX polyclonal primary antibodies (280 ng/ml) (12) and HRP conjugated anti-rabbit secondary antibody (KPL, 1:2000) followed by chemiluminescence autoradiography. Actin was detected using monoclonal antiactin antibody (ICN biomedicals, Burlingame, CA, 1:1000) and HRP conjugated anti-mouse secondary antibody (KPL, 1:5000). Quantitation of western blot autoradiographs was done using a Kodak digital science Image Station 440CF.
Statistical methods
Univariate analysis of clinical-pathological parameters based on WWOX staining was determined by v 2 test with Yates' correction. Ordinal-by-ordinal association was assessed by Kendall's tau-b test. Pearson's test was used to analyze the correlation between WWOX staining intensity and number of lymph node status and patient age at diagnosis for DCIS and IDCA lesions. The basic significance level was fixed at p < 0.05 and all data was analyzed using SPSS Ò statistical software (Version 11.0; SPSS Inc., Chicago, IL).
Results
Loss of WWOX expression in pre-invasive and invasive breast cancer WWOX staining was detected in all normal mammary epithelial samples (16 out of 16). The pattern of Figure 2 and the statistical significant differences are indicated in Table 2 . As can be observed, both in Figure 2A and Table 2 , there is a trend for the reduction of WWOX expression from in situ carcinoma lesions to the more advanced fully invasive lesions. However, no statistically significant associations were detected between levels of WWOX expression and other predictors of tumor aggressiveness such as lymph node status, metastasis status, clinical staging or nuclear grade. In addition, no association was found with age of the patient at time of diagnosis. It is worth reporting that in every normal and tumor sample analyzed by immunostaining in which WWOX expression was detected, the staining was always cytoplasmic, not a single case out of the 235 samples analyzed showed nuclear WWOX staining. These observations are in sharp contrast with a previous report in which WWOX cytoplasmic and nuclear staining was observed in some cells from normal mammary epithelium [16] . The reason for this discrepancy is unclear but in that report the number of normal cases analyzed was not indicated and only one microphotograph of one mammary lobular structure was shown with the majority of epithelial cells displaying only cytoplasmic staining.
WWOX expression correlates with ER status
When WWOX staining and ER status were considered we observed an interesting statistically significant correlation between levels of WWOX expression and ER status, 27% of ER+ breast carcinomas were completely negative for WWOX expression versus 46% for ERÀ cases ( p=0.0054) ( Table 2 ). This correlation was even more significant when the WWOX negative category plus the weakly stained category were considered as a single group compared to the strongly staining category. In this case the sum of both categories increased to 73% of cases (i.e. negative + weak) for the ERÀ group and 51% for the ER+ group respectively (p=0.003) (Figure 2B , Table 2 ).
We also performed the same type of analysis but now incorporating the PR status, thus determining four groups due to all possible combination on the status of both receptors. The ERÀ PRÀ group showed the highest number of WWOX negative cases amounting to 51% (28 out of 55), increasing to a dramatic 80% of cases (44 out of 55) if we include the weak-staining category. This group was significantly different from the three other groups with a p=0.013 ( Figure 2C , Table 2 ). Interestingly, the ERÀ PR+ group did not behave statistically differently than the ER+ groups. However the small number of samples of this specific group (11 cases) did not allow us to draw strong conclusions on this observation ( Figure 2C ). Representative microphotographs illustrating the association of WWOX expression with ER expression are shown in Figure 3 .
Western blot analysis of WWOX expression in invasive breast carcinomas
Western blot analyses were performed using protein extracts obtained from 23 invasive ductal breast carcinoma samples, as control normal epithelial organoids were isolated from normal mammoplasty specimens. The normal epithelial organoids express very high levels of WWOX protein as can be observed in Figure 4 , samples B30, B32 and B42. This is consistent with the immunohistochemical observations described above ( Figure 1A and B) . Breast carcinomas demonstrated variable levels of WWOX expression with some tumors expressing significant amounts of WWOX protein, e.g. T82 in Figure 4 , while other tumors displayed barely detectable, if any, WWOX protein. The relative intensity of each reactive WWOX band was normalized to Actin, used as loading control. The values obtained were in turn expressed relative to the levels detected in the breast epithelial organoids. We concluded that 20 out of the 23 tumors (87%) expressed WWOX protein at levels lower than 50% that of WWOX protein in the normal . WWOX protein levels in normal and tumor breast tissue. Immunodetection of WWOX in human tissue extracts. Human breast protein extracts were separated by 12.5% SDS-PAGE and transferred to PVDF membranes. WWOX protein was detected using affinity purified rabbit polyclonal anti-WWOX antibody. The membrane was then probed with mouse monoclonal anti-actin antibody for normalization of differences in protein loading. Three normal human protein extracts prepared from breast organoids were included on each gel. WWOX protein levels in 23 breast tumors showed significant differences compared to normal breast WWOX levels. The full-length WWOX protein is indicated. NEG. -negative control extract (PEO1 cell line) that does not express WWOX protein. Rel. Exp. = Relative WWOX Expression. WWOX expression in each sample was first normalized to actin to correct for loading differences. WWOX expression in tumors relative to WWOX levels in normal organoids was then determined using the actin normalized values.
mammary epithelial organoid preparations. This analysis is in agreement with the immunohistochemical studies, indicating that a high proportion of breast carcinomas expressed significantly reduced levels of WWOX protein. Importantly, the western blot analysis also demonstrates that the antibody used in our studies detects only full-length WWOX protein in both normal and tumors.
Discussion
In the original report describing the cloning of WWOX, we observed that expression of this gene at the RNA level was highly variable among breast carcinoma lines. Some breast cancer lines showed no expression of the WWOX transcript while other lines overexpressed WWOX as detected by Northern and RT-PCR analyses [7, 11] . Interestingly the breast cancer line that expresses by far the highest levels of WWOX mRNA and protein was the ER+ breast cancer line MCF7. The T47D ER+ breast cancer line also expresses WWOX protein, while the ERÀ and aggressive lines such as MDA435 and MDA231 showed practically undectable levels of this protein [12] . This early data already appeared to indicate a possible association between WWOX expression and ER status. We also previously reported that WWOX is highly expressed in organs with high production of sex steroid hormones such as testis, prostate and ovaries [7] . In our original analysis of the short chain dehydrogenase domain of WWOX, we observed that this oxidoreductase enzyme displays a putative signature suggestive of function, which is a serine residue 12 amino acids upstream of the YNRSK substrate-binding motif. This serine is at a nearly identical location to that observed in steroid dehydrogenases (usually position À13 from Tyr), which is suggested to play an important role in the catalysis of steroid substrates [17] . Based on these observations we speculated that WWOX might play a role in sex-steroid metabolism.
In this study we report a striking statistically significant correlation between WWOX expression and ER status in breast carcinomas. A higher proportion of ER+ breast carcinomas express more WWOX than the ERÀ counterparts. In our studies, due to the limited number of ERÀ PR+ breast carcinoma samples, we could not rule out that PR+ status alone correlates to high WWOX expression.
These findings further strengthen the hypothesis that WWOX plays a role in sex-steroid metabolism and very likely functions in a pathway or pathways associated with the estrogen-progesterone axis. Interestingly, it has been demonstrated that estradiol concentrations are much higher in breast carcinomas than in normal breast tissue and approximately 50 to 100-fold higher than circulating levels of this hormone in post-menopausal women. It is also known that for the most part the higher tumor estradiol levels are the result of in situ synthesis [Reviewed in 18]. Perhaps the higher levels of WWOX protein found mostly in ER+ tumors and estradiol dependent breast cancer cell lines is somehow associated to the aforementioned tumor in situ estradiol synthesis phenomenon.
WWOX was originally cloned due to its mapping to a locus affected by a high frequency of gross genomic rearrangements including, losses of heterozygosity as a consequence of large deletions, recombination or chromosomal translocations [7] . However other investigators have shown in leukemias that epigenetic mechanisms could also play a role in loss of expression of this protein [10] .
This locus was identified to be that of the second most common chromosomal fragile site, FRA16D [7, 19, 20] . Hemi and homozygous genomic losses have been traditionally considered a hallmark of tumor suppressor activity at the loci of origin. In spite of the fact that the majority of currently existent breast cancer lines are hemizygous for WWOX we failed to identify mutations in the remaining active alleles, we only observed homozygous losses affecting intronic regions and lack of expression in aggressive breast cancer lines [7, 12] . However, homozygous losses affecting WWOX were later demonstrated in ovarian, lung carcinoma cell lines and other tumor cell types [8] . We demonstrated that when ectopically expressed in aggressive breast cancer lines, WWOX behaves as an inhibitor of anchorage independent growth and of in vivo tumorigenesis [11] . Thus, WWOX could also be classified as a 'putative' tumor suppressor gene.
In this report we demonstrate that WWOX is abundantly expressed in normal human breast epithelium both by immunohistochemistry and Western analysis. In agreement with the behavior of classical tumor suppressor genes, we observed a complete loss of expression in over a third (34%) of invasive breast carcinomas. This percentage increases up to 60% of cases when we include carcinomas with very weak WWOX expression. We also determined that reduced WWOX expression is also observed in a third of preinvasive lesions (DCIS).
A main question arising from these studies is whether the loss of WWOX expression is causatively associated with tumor development or a consequence of tumor progression. The fact that we find a tendency for lower WWOX expression in invasive lesions when compared to DCIS makes the second alternative more likely (i.e. expression loss occurring during tumor progression). However, the fact that 80% of ER negative cases demonstrate loss or reduced expression of WWOX also raises the possibility that at least some of those tumors may represent a subclass of lesions in which WWOX loss could be a causative event. While this manuscript was in preparation Guler et al. [21] reported similar observations of WWOX protein expression in a study of 97 breast carcinomas. It is still an issue of controversy whether ERÀ status simply represents a stage of progression or that subsets of breast carcinomas originate as ERÀ negative lesions.
In summary, two main conclusions can be drawn from these studies, first that loss of WWOX expression is a frequent event in breast cancer and second that a strong correlation with WWOX expression and ER status is observed. Further studies will be necessary to elucidate whether loss of WWOX expression is an early causative event at least in a subset of tumors, or whether this event predominantly occurs during breast carcinoma progression.
